C4 therapeutics reports fourth quarter and full year 2022 financial results and recent business highlights

Phase 1 dose escalation data from the ongoing phase 1/2 clinical trials of cft7455, an ikzf1/3 monodac™ degrader, and cft8634, a brd9 bidac™ degrader, expected in 2h 2023
CCCC Ratings Summary
CCCC Quant Ranking